Virtu Financial LLC purchased a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 132,482 shares of the company’s stock, valued at approximately $391,000. Virtu Financial LLC owned 0.25% of cbdMD as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of YCBD. AdvisorShares Investments LLC increased its holdings in shares of cbdMD by 66.5% during the fourth quarter. AdvisorShares Investments LLC now owns 1,439,725 shares of the company’s stock valued at $4,247,000 after acquiring an additional 574,997 shares in the last quarter. Penserra Capital Management LLC increased its holdings in shares of cbdMD by 128.0% during the fourth quarter. Penserra Capital Management LLC now owns 222,334 shares of the company’s stock valued at $654,000 after acquiring an additional 124,812 shares in the last quarter. CAPROCK Group Inc. bought a new stake in shares of cbdMD during the fourth quarter valued at approximately $295,000. Squarepoint Ops LLC bought a new stake in shares of cbdMD during the third quarter valued at approximately $187,000. Finally, ETF Managers Group LLC bought a new stake in shares of cbdMD during the fourth quarter valued at approximately $98,000.
Shares of NYSEAMERICAN YCBD opened at $3.59 on Thursday. cbdMD, Inc. has a one year low of $0.78 and a one year high of $6.83. The business’s fifty day moving average price is $2.88 and its 200-day moving average price is $2.54.
Several equities research analysts recently issued reports on YCBD shares. Zacks Investment Research upgraded cbdMD from a “sell” rating to a “hold” rating in a report on Thursday, April 1st. Cantor Fitzgerald upped their price target on cbdMD from $3.60 to $4.30 and gave the stock a “neutral” rating in a report on Friday, January 29th.
In other cbdMD news, Director William F. Raines III sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 2nd. The stock was sold at an average price of $4.04, for a total value of $80,800.00. Following the sale, the director now owns 1,342 shares of the company’s stock, valued at approximately $5,421.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Martin A. Sumichrast sold 59,507 shares of the firm’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $4.04, for a total value of $240,408.28. The disclosure for this sale can be found here. Insiders have sold a total of 484,003 shares of company stock worth $2,093,436 in the last three months.
cbdMD, Inc produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.